全文获取类型
收费全文 | 87篇 |
免费 | 4篇 |
专业分类
儿科学 | 5篇 |
基础医学 | 10篇 |
口腔科学 | 5篇 |
临床医学 | 5篇 |
内科学 | 16篇 |
皮肤病学 | 1篇 |
神经病学 | 3篇 |
特种医学 | 4篇 |
外科学 | 8篇 |
预防医学 | 6篇 |
眼科学 | 6篇 |
药学 | 19篇 |
肿瘤学 | 3篇 |
出版年
2021年 | 2篇 |
2015年 | 1篇 |
2014年 | 1篇 |
2013年 | 2篇 |
2011年 | 4篇 |
2010年 | 6篇 |
2009年 | 7篇 |
2008年 | 1篇 |
2007年 | 1篇 |
2006年 | 1篇 |
2005年 | 2篇 |
2004年 | 2篇 |
2003年 | 2篇 |
2002年 | 5篇 |
2001年 | 4篇 |
2000年 | 6篇 |
1998年 | 5篇 |
1997年 | 11篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1990年 | 1篇 |
1989年 | 5篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1985年 | 2篇 |
1983年 | 2篇 |
1980年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有91条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
IG Azcárate P Marín-García N Camacho S Pérez-Benavente A Puyet A Diez L Ribas de Pouplana JM Bautista 《British journal of pharmacology》2013,169(3):645-658
Background and Purpose
Blood-stage Plasmodium parasites cause morbidity and mortality from malaria. Parasite resistance to drugs makes development of new chemotherapies an urgency. Aminoacyl-tRNA synthetases have been validated as antimalarial drug targets. We explored long-term effects of borrelidin and mupirocin in lethal P. yoelii murine malaria.Experimental Approach
Long-term (up to 340 days) immunological responses to borrelidin or mupirocin were measured after an initial 4 day suppressive test. Prophylaxis and cure were evaluated and the inhibitory effect on the parasites analysed.Key Results
Borrelidin protected against lethal malaria at 0.25 mg·kg−1·day−1. Antimalarial activity of borrelidin correlated with accumulation of trophozoites in peripheral blood. All infected mice treated with borrelidin survived and subsequently developed immunity protecting them from re-infection on further challenges, 75 and 340 days after the initial infection. This long-term immunity in borrelidin-treated mice resulted in negligible parasitaemia after re-infections and marked increases in total serum levels of antiparasite IgGs with augmented avidity. Long-term memory IgGs mainly reacted against high and low molecular weight parasite antigens. Immunofluorescence microscopy showed that circulating IgGs bound predominantly to late intracellular stage parasites, mainly schizonts.Conclusions and Implications
Low borrelidin doses protected mice from lethal malaria infections and induced protective immune responses after treatment. Development of combination therapies with borrelidin and selective modifications of the borrelidin molecule to specifically inhibit plasmodial threonyl tRNA synthetase should improve therapeutic strategies for malaria. 相似文献15.
16.
Background
During a previous study to define and compare incidence risks of postoperative nausea and vomiting (PONV) for elective laparoscopic and open cholecystectomy at two hospitals in Jamaica, secondary analysis comparing PONV risk in elective open cholecystectomy to that after emergency open cholecystectomy suggested that it was markedly reduced in the latter group. The decision was made to collect data on an adequate sample of emergency open cholecystectomy cases and further explore this unexpected finding in a separate study. 相似文献17.
18.
Interleukin-5 is at 5q31 and is deleted in the 5q- syndrome 总被引:3,自引:0,他引:3
Sutherland GR; Baker E; Callen DF; Campbell HD; Young IG; Sanderson CJ; Garson OM; Lopez AF; Vadas MA 《Blood》1988,71(4):1150-1152
Human interleukin-5 (IL-5) is a selective eosinophilopoietic and eosinophil-activating growth hormone. By in situ hybridization this gene is mapped to chromosome 5q23.3 to 5q32. It is shown to be deleted in two patients with the 5q-syndrome and in one patient previously diagnosed with myelodysplasia whose condition had progressed to acute myeloblastic leukemia. The clustering of other genes involved in hematopoiesis (IL-3, granulocyte-macrophage colony-stimulating factor, feline sarcoma viral oncogene homolog, colony-stimulating factor 1) to the same region as IL-5 suggests a nonrandom localization and raises interesting questions concerning the evolution and regulation of these genes. 相似文献
19.
Erythropoietin and sexual dysfunction 总被引:7,自引:1,他引:6
Lawrence IG; Price DE; Howlett TA; Harris KP; Feehally J; Walls J 《Nephrology, dialysis, transplantation》1997,12(4):741-747
BACKGROUND: Erythropoietin (rHuEpo) therapy has been shown to improve
sexual function in the male dialysis population, with several studies
suggesting a direct effect upon endocrine function, as well as correction
of anaemia. Nevertheless many male dialysis patients receiving rHuEpo
continue to complain of sexual dysfunction. METHODS: At a dedicated renal
impotence clinic, 65 male dialysis patients were screened for endocrine
disturbances. Baseline serum sex hormones were compared between those
receiving and not receiving rHuEpo, using either the two-sample t test or
the Mann-Whitney U test, after assessing for normality. Results from four
patients were excluded on account of either medications (antiemetic
phenothiazines), hepatic dysfunction, or carcinomatosis. RESULTS:
Twenty-five patients (41.0%) were receiving rHuEpo, the recipients and
non-recipients being well matched for haemoglobin (10.19 +/- 0.29 vs 10.55
+/- 0.25 g/dl, n.s.), age (51.1 +/- 1.9 vs 53.6 +/- 2.1 years, n.s.) and
duration of sexual dysfunction (median, 3.0 vs 3.0 years, n.s.). The rHuEpo
recipients had a higher median creatinine (1090 vs 972 micromol/l, P <
0.02), but similar nutritional status to the non-recipients (albumin 41.0
vs 39.0 g/l, n.s.). The total duration of rHuEpo therapy was 0.85 +/- 0.14
years. Prolactin levels were similar in both the rHuEpo recipients and non-
recipients (440 vs 541 mu/l, n.s.), as were LH (11.0 vs 10.5 iu/l, n.s.)
and FSH (8.0 vs 6.5 iu/l, n.s.). However, there were significant elevations
of testosterone (19.8 +/- 1.3 vs 16.1 +/- 1.1 nmol/l, P < 0.05) and sex
hormone binding globulin (SHBG) (40.5 vs 26.0 nmol/l, P < 0.01), with a
trend toward elevated oestradiol (304 vs 248 pmol/l, P = 0.095) in the
rHuEpo-treated group. Forty-eight subjects (78.7%) received peritoneal
dialysis (PD), with the 19 rHuEpo recipients (39.6%) demonstrating
increased serum testosterone (21.0 +/- 1.5 vs 16.6 +/- 1.3 nmol/l, P <
0.05), SHBG (40.5 vs 26.5 nmol/l, P < 0.01), LH (15.0 vs 10.0 iu/l, P
< 0.01) and FSH (12.0 vs 5.3 iu/l, P < 0.05). These differences were
not demonstrated in the 13 haemodialysis (HD) subjects. CONCLUSIONS: Male
dialysis patients complaining of sexual dysfunction after correction of
anaemia with rHuEpo are characterized by higher levels of serum
testosterone and SHBG, but not suppression of hyperprolactinaemia or
hyperoestrogenism. Male PD subjects receiving rHuEpo also demonstrated
increased LH and FSH.
相似文献
20.